Klcm Advisors, Inc. Bristol Myers Squibb CO Transaction History

Klcm Advisors, Inc.

$820 Million
Q3 2024

A detailed history of Klcm Advisors, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Klcm Advisors, Inc. holds 555,582 shares of BMY stock, worth $31.6 Million. This represents 3.51% of its overall portfolio holdings.

Number of Shares

555,582

Previous 421,755 31.73%

Holding current value

$31.6 Million

Previous $17.5 Million 64.15%

% of portfolio

3.51%

Previous 2.21%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 06, 2024	BUY	$39.66 - $51.75 $5.31 Million - $6.93 Million	133,827 Added 31.73%	555,582 $28.8 Million
Q2 2024 Aug 13, 2024	BUY	$40.25 - $52.99 $1.26 Million - $1.66 Million	31,252 Added 8.0%	421,755 $17.5 Million
Q1 2024 May 16, 2024	SELL	$47.98 - $54.4 $9,020 - $10,227	-188 Reduced 0.05%	390,503 $21.2 Million
Q4 2023 Jan 30, 2024	BUY	$48.48 - $57.85 $3.72 Million - $4.44 Million	76,740 Added 24.44%	390,691 $20 Million
Q3 2023 Nov 07, 2023	BUY	$57.89 - $64.73 $257,610 - $288,048	4,450 Added 1.44%	313,951 $18.2 Million
Q2 2023 Aug 08, 2023	BUY	$63.71 - $70.74 $166,729 - $185,126	2,617 Added 0.85%	309,501 $19.8 Million
Q1 2023 May 11, 2023	BUY	$65.71 - $74.53 $463,518 - $525,734	7,054 Added 2.35%	306,884 $21.3 Million
Q4 2022 Feb 10, 2023	BUY	$68.48 - $81.09 $81,491 - $96,497	1,190 Added 0.4%	299,830 $21.6 Million
Q3 2022 Nov 14, 2022	BUY	$0.13 - $76.84 $1,317 - $779,003	10,138 Added 3.51%	298,640 $21.2 Million
Q2 2022 Aug 04, 2022	SELL	$72.62 - $79.98 $3.83 Million - $4.22 Million	-52,796 Reduced 15.47%	288,502 $22.2 Million
Q1 2022 May 03, 2022	BUY	$61.48 - $73.72 $848,854 - $1.02 Million	13,807 Added 4.22%	341,298 $24.9 Million
Q4 2021 Jan 31, 2022	BUY	$53.63 - $62.52 $525,681 - $612,821	9,802 Added 3.09%	327,491 $20.4 Million
Q3 2021 Nov 16, 2021	BUY	$59.17 - $69.31 $746,192 - $874,068	12,611 Added 4.13%	317,689 $18.8 Million
Q2 2021 Aug 03, 2021	BUY	$61.91 - $67.42 $946,418 - $1.03 Million	15,287 Added 5.28%	305,078 $20.4 Million
Q1 2021 Apr 21, 2021	BUY	$59.34 - $66.74 $528,363 - $594,252	8,904 Added 3.17%	289,791 $18.3 Million
Q4 2020 Jan 26, 2021	SELL	$57.74 - $65.43 $179,860 - $203,814	-3,115 Reduced 1.1%	280,887 $17.4 Million
Q3 2020 Nov 03, 2020	SELL	$57.43 - $63.64 $986,647 - $1.09 Million	-17,180 Reduced 5.7%	284,002 $17.1 Million
Q2 2020 Jul 27, 2020	SELL	$54.82 - $64.09 $860,564 - $1.01 Million	-15,698 Reduced 4.95%	301,182 $17.7 Million
Q1 2020 May 13, 2020	SELL	$46.4 - $67.43 $774,184 - $1.13 Million	-16,685 Reduced 5.0%	316,880 $17.7 Million
Q4 2019 Feb 04, 2020	SELL	$49.21 - $64.19 $203,729 - $265,746	-4,140 Reduced 1.23%	333,565 $21.4 Million
Q3 2019 Nov 12, 2019	BUY	$42.77 - $50.71 $973,017 - $1.15 Million	22,750 Added 7.22%	337,705 $17.1 Million
Q3 2019 Nov 04, 2019	SELL	$42.77 - $50.71 $213,422 - $253,042	-4,990 Reduced 1.58%	310,180 $15.7 Million
Q3 2019 Nov 04, 2019	BUY	$42.77 - $50.71 $204,226 - $242,140	4,775 Added 1.54%	314,955 $16 Million
Q2 2019 Aug 15, 2019	BUY	$44.62 - $49.34 $6.4 Million - $7.07 Million	143,328 Added 83.41%	315,170 $14.3 Million
Q1 2019 May 14, 2019	BUY	$45.12 - $53.8 $7.75 Million - $9.25 Million	171,842 New	171,842 $8.2 Million
Q1 2018 May 10, 2018	SELL	$59.92 - $68.98 $241,597 - $278,127	-4,032 Closed	0 $0
Q4 2017 Feb 15, 2018	SELL	$59.94 - $65.35 $239,760 - $261,399	-4,000 Reduced 49.8%	4,032 $247,000
Q3 2017 Nov 14, 2017	SELL	$55.23 - $63.74 $115,983 - $133,854	-2,100 Reduced 20.73%	8,032 $512,000
Q2 2017 Aug 15, 2017	BUY	N/A	10,132	10,132 $565,000

Others Institutions Holding BMY

# of Institutions

2,537

Shares Held

1.47B

Call Options Held

31.6M

Put Options Held

35M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $121B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Klcm Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Klcm Advisors, Inc. with notifications on news.

Account

Klcm Advisors, Inc. Bristol Myers Squibb CO Transaction History